Robert Iannone - 09 Jul 2026 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Reporting relationship: Director
Issuer ticker: PLRX
Reported as of: 09 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jul 2026, 16:32:28 UTC
Prior SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Woo, attorney-in-fact

Key filing fact

Robert Iannone filed Form 4 for PLIANT THERAPEUTICS, INC. (PLRX) on 13 Jul 2026.

Key facts

This page summarizes Robert Iannone's Form 4 filing for PLIANT THERAPEUTICS, INC. (PLRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Jul 2026, 16:32.

Change

Previous filing in this sequence was filed on 02 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001737329 Primary reporting owner

Iannone Robert

Relationship: Director
Address: C/O PLIANT THERAPEUTICS, INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO
Signature: /s/ Jennifer Woo, attorney-in-fact
Signature date: 13 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PLRX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +60,000
Change %
Price: $0.000000^*
Shares after: 60,000
Date: 09 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 60,000
Exercise price: $1.13
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/36th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of July 9, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.